BioPharma DiveOriginal article
AstraZeneca’s newly approved pill fails frontline breast cancer study
Phase 3negativeEtcamahNegative
AI Analysis
Summary
AstraZeneca's oral SERD drug Etcamah failed a first-line breast cancer study, marking the second SERD to fall short in this indication following Roche's earlier setback this year.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Failed frontline breast cancer study
Importance:7/10
Sentiment:
-0.90
breast cancerSERDoral medicationclinical trial failurefirst-line therapy
Related Companies
Read the original article
Published by BioPharma Dive on September 14, 2026 4:30 PM